Announcement • May 12

Viking Therapeutics, Inc. Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735

Viking Therapeutics, Inc. presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation of VK2735 at the European Congress on Obesity (ECO) in Istanbul, Türkiye. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development with subcutaneous and oral formulations for the potential treatment of various metabolic disorders. The poster presented now at ECO 2026 highlighted key findings from previously reported trial data, including mean change from baseline in body weight throughout the 13-week treatment period and additional safety and tolerability data, for the Phase 2 study of orally administered VK2735. Participants receiving once-daily oral VK2735 demonstrated statistically significant, dose-dependent weight loss from baseline of up to 12.2% (26.6 lbs) at 13 weeks across all dose cohorts. Compared with placebo, doses >15 mg demonstrated dose-dependent and progressive weight loss starting early in treatment and continuing through the 13-week treatment window, with no plateau. Up to 97% of VK2735-treated participants achieved =5% weight loss, and up to 80% achieved =10%, compared with 10% and 5%, respectively, for placebo. VK2735 was well tolerated, with the vast majority of treatment-emergent adverse events (TEAEs) reported as mild or moderate in severity. These events typically occurred early in treatment and resolved with continued dosing. The study population was similar to patients typically encountered in clinical practice, with an average BMI of 37 and average age of 51 years. Similar to patients seen in clinical practice, there was a high prevalence of cardiometabolic risk factors, including pre-diabetes (54%). Across all dose cohorts, the male-to-female ratio ranged from 15:85 to 45:55. Highlights from Viking's poster titled Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding VENTURE-2 Study include: Early and progressive weight loss. Patients receiving VK2735 experienced statistically significant reductions in body weight compared with placebo, beginning as early as Week 1 at all doses greater than 15 mg, with continuous and progressive weight loss observed throughout the 13-week treatment period. No plateau observed. Weight loss trajectories demonstrate continued downward trends across all active dose levels through Week 13, supporting the potential for continued weight reduction with longer-duration treatment. Dose-dependent efficacy. Weight loss increased with escalating doses of VK2735, with the highest dose achieving a mean reduction of up to 12.2% of body weight from baseline at Week 13. Favorable tolerability profile. Among subjects receiving VK2735, the majority (98%) of reported drug-related TEAEs were categorized as mild or moderate in severity. Gastrointestinal-related events were the most commonly observed TEAEs and were consistent with dual agonist GLP-1/GIP receptors, typically occurring early in treatment and subsiding with continued dosing. Progressive titration enabled tolerability. Dose escalation in 30 mg increments enabled rapid progression to higher dose levels with an encouraging tolerability profile, and gastrointestinal events diminished over time. Lower starting doses and longer titration windows may further improve tolerability.

Announcement • May 07

Viking Therapeutics, Inc. Announces Two Poster Presentations on Vk2735 Program At European Congress on Obesity

Viking Therapeutics, Inc. announced that it will present two posters on its VK2735 program at the 33European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity. At ECO, Viking will present a poster highlighting data from its Phase 2 VENTURE-Oral Dosing trial, focusing on key efficacy and safety endpoints, including weight loss and tolerability during the 13-week study. The second poster will highlight the design and enrollment demographics of the ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with obesity or who are overweight and have at least one weight-related comorbidity. Title: Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding VENTURE-Oral Study. VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the treatment of metabolic disorders, including obesity. The compound is being evaluated in both oral and subcutaneous formulations. Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound.

Viking Therapeutics, Inc. Stock Price

VKTX Share Price Performance

VKTX Community Narratives

Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis

Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play

Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play

Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis

Trending Discussion

Recently Updated Narratives

Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play

Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis

Snowflake Analysis

Viking Therapeutics, Inc. Key Details

About VKTX

Recent VKTX News & Updates

Viking Therapeutics Completes Phase 3 Enrollment for VK2735 and Reports Up to 12.2% Weight Loss

Viking Therapeutics, Inc. Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735

Viking Therapeutics, Inc. Announces Two Poster Presentations on Vk2735 Program At European Congress on Obesity

Recent updates

Viking Therapeutics, Inc. Competitors

Incyte

Viatris

Moderna

Neurocrine Biosciences